Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms

Experimental Neurology

Volumn 132, Issue 1, 1995, Pages 62-76

  Lindner, Mark D ^a   Winn, Shelley R ^a   Baetge, E E ^a   Hammang, Joseph P ^a   Gentile, Frank T ^a   Doherty, Ed ^a   McDermott, Patricia E ^a   Frydel, Beata ^a   Ullman, M David ^a   Schallert, Timothy ^b   Emerich, Dwaine F ^a  

^a CytoTherapeutics Inc   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; LEVODOPA; OXIDOPAMINE;

AKINESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ENCAPSULATION; HAMSTER; NERVE TRANSPLANTATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMAL; BASE SEQUENCE; BEHAVIOR, ANIMAL; CAPSULES; CELL LINE; CLONING, MOLECULAR; CORPUS STRIATUM; DOPAMINE; DRUG IMPLANTS; KIDNEY; LEVODOPA; MALE; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; OXIDOPAMINE; PARKINSON DISEASE; PC12 CELLS; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; TYROSINE 3-MONOOXYGENASE;

EID: 0028917168     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/0014-4886(95)90059-4     Document Type: Article

References (75)

1. Functional recovery in hemiparkinsonian primates transplanted with polymer-encapsulated PC12 cells
2. Long-term cross-species brain transplantation of a polymer-encapsulated dopamine-secreting cell line
3. Adrenal medullary transplantation into the brain for treatment of Parkinson's disease: Clinical outcome and neurochemical studies
4. Depletion of dopamine in the caudate nucleus but not in nucleus accumbens impairs reaction-time performance in rats
5. Neurite outgrowth in PC12 cells deficient in GAP-43
6. Complete nucleotide and deduced amino acid sequence of bovine phenylethanolamine N-methyltransferase: Partial amino acid homology with rat tyrosine hydroxylase
7. Human ballistic arm abduction movements: Effects of L-DOPA treatment in Parkinson's disease
8. Comparison of adrenal medullary, carotid body and PC12 cell grafts in 6-OHDA lesioned rats
9. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings)
10. Reinnervation of the denervated striatum by substantia nigra transplants: Functional consequences as revealed by pharmacological and sensorimotor testing
11. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy
12. Role of the neostriatal dopaminergic activity in sequencing and selecting behavioural strategies: Facilitation of processes involved in selecting the best strategy in a stressful situation
13. Different effects of nucleus accumbens and ventrolateral striatal dopamine depletions on instrumental response selection in the rat
14. Cografts of adrenal medulla with peripheral nerve enhance the survivability of transplanted adrenal chromaffin cells and recovery of the host nigrostriatal dopaminergic system in MPTP-treated young adult mice
15. Parkinsonism and levodopa: A five-year experience
16. Computational procedures for estimating magnitude of effect for some analysis of variance designs
17. Intracerebral grafting of neuronal cell suspensions IV. Behavioural recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites
18. Grafts of embryonic nigra reinnervating the ventrolateral striatum ameliorate sensorimotor impairments and akinesia in rats with 6-OHDA lesions of the nigrostriatal pathway
19. Behavioural recovery following transplantion of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions
20. Sensorimotor impairments following localized kainic acid and 6-hydroxydopamine lesions of the neostriatum
21. Transplantation of polymer encapsulated PC12 cells: Use of chitosan as an immobilization matrix
22. Polymer-encapsulated PC12 cells promote recovery of motor function in aged rats
23. Intrastriatal implants of polymer-encapsulated PC12-cells—Effects on motor function in aged rats
24. Effects of unilateral 6-hydroxydopamine lesions of the caudate-putamen on skilled forepaw use in the rat
25. Dopamine in the lateral caudate-putamen of the rat is essential for somatosensory orientation
26. Properties of PC12 pheochromocytoma cells transplanted to the adult rat brain
27. Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data
28. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor
29. Implantation of PC12 cells into the corpus striatum of rats with lesions of the dopaminergic nigrostriatal neurons
30. Parkinson's disease and its chemotherapy
31. A clinicopathologic study of 100 cases of Parkinson's disease
32. Comparison of motor response to apomorphine and levodopa in Parkinson's disease
33. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease
34. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease
35. Dopamine agonists in Parkinson's disease: A look at apomorphine
36. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons
37. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease
38. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease
39. Evidence for Long-Term Survival and Function of Dopaminergic Grafts in Progressive Parkinsons Disease
40. Transplantation of fetal dopamine neurons in Parkinson's disease: One-year clinical and neurophysiological observations in two patients with putaminal implants
41. CNS compensation to dopamine neuron loss in Parkinson's disease
42. Levodopa-induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification
43. The mysterious motor function of the basal ganglia: The Robert Warternberg Lecture
44. Somatosensory inattention after dopaminedepleting intracerebral 6-OHDA injections: Spontaneous recovery and pharmacological control
45. Neostriatal dopamine and sensory inattention
46. Sensory inattention in rats with 6-hydroxydopamine-induced degeneration of ascending dopaminergic neurons: Apomorphine-induced reversal of deficits
47. Initial treatment of Parkinson's disease
48. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system
49. Time course of nigrostriatal degeneration in Parkinson's disease
50. Motor planning is impaired in Parkinson's disease
51. Dopamine depletion in a striatal subregion disrupts performance of a skilled motor task in the rat
52. The role of brain dopamine in response initiation: Effects of haloperidol and regionally specific dopamine depletions on the local rate of instrumental responding
53. Ventrolateral striatal dopamine depletions impair feeding and food handling in rats
54. Dopamine deficiency in the cerebral cortex in Parkinson disease
55. Regional and cell-specific expression of GDNF in rat brain
56. Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism
57. ‘Disengage’ sensorimotor deficit following apparent recovery from unilateral dopamine depletion
58. A clinically relevant unilateral rat model of Parkinsonian akinesia
59. Rescuing neurons from trans-synaptic degeneration after brain damage: Helpful, harmful, or neutral in recovery of function?
60. Tactile extinction: Distinguishing between sensorimotor and motor asymmetries in rats with unilateral nigrostriatal damage
61. Posture-independent sensorimotor analysis of interhemispheric receptor asymmetries in neostriatum
62. Current strategies in the drug treatment of advanced Parkinson's disease—New modes of dopamine substitution
63. Striatal dopamine deficiency in Parkinson's disease: Role of aging
64. Effects of mood, motivation, stress and alertness on the performance in Parkinson's disease
65. Reactive capacity: A sensitive behavioral marker of movement initiation and nigrostriatal dopamine function
66. Functional reinnervation of the denervated neostriatum by nigral transplants
67. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo
68. Chronic implants of chromaffin tissue into the dopamine-denervated striatum Effects of NGF on graft survival fiber growth and rotational behavior
69. Polymer encapsulated neurotransmitter secreting cells: Potential treatment for Parkinson's disease
70. Polymer-encapsulated PC12 cells: Long-term survival and associated reduction in lesion-induced rotational behavior
71. Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons
72. Polymer-encapsulated cells genetically modified to secrete human nerve growth factor promote the survival of axotomized septal cholinergic neurons
73. Behavioral recovery following intrastriatal implantation of microencapsulated PC12 cells
74. A Long Term Follow-Up of Fetal Dopaminergic Neurons Transplantation into the Brain of Three Parkinsonian Patients